熱門資訊> 正文
Mainz Biomed定价400万美元证券发行
2025-05-20 16:38
- Mainz Biomed (NASDAQ:MYNZ) has priced a follow-on offering of 2M units to raise gross proceeds of approximately $4M.
- Each unit, consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share, is being sold at an effective offering price of $2.00 per unit.
- Each Series A warrant will be immediately exercisable at $2.00 per share and will expire five years from the date of issuance.
- Each Series B warrant will be immediately exercisable at $2.00 per share and will expire on the earlier of (i) 30 days following receipt of results from the company’s eAArly Detect 2 study, and (ii) one year from the date of issuance.
- The offering is expected to close on or about May 21, 2025, subject to customary closing conditions.
- Source: Press Release
More on Mainz Biomed B.V.
- Mainz Biomed launches public offering of units and warrants
- Mainz Biomed expands into Switzerland with labor team w
- Seeking Alpha’s Quant Rating on Mainz Biomed B.V.
- Historical earnings data for Mainz Biomed B.V.
- Financial information for Mainz Biomed B.V.
推薦文章
港股周報丨三家外賣平臺被約談！「瘋狂星期六」或不再瘋狂；花旗呼籲增持中國互聯網、科技及消費板塊
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
